FGFR2 and cholangiocarcinoma: Given the encouraging signs of activity reported in FOENIX-CCA 2, the ongoing phase III FOENIX-CCA3 clinical trial is comparing futibatinib versus cisplatin–gemcitabine as a first-line treatment for locally advanced unresectable or metastatic iCCA patients harboring FGFR2 gene fusions or rearrangements.